Heptares Therapeutics heptares.com


Public list: BIO 2016 (619) Pharma Startups (4732)

Heptares Therapeutics focuses on the discovery and development of novel drugs acting at G-protein coupled receptors (GPCRs). Heptares StaR (Stabilized Receptor) technology enables thermo-stabilization of GPCRs, a breakthrough allowing X-ray crystallography of conformationally-constrained receptors, thereby facilitating structure-based drug design at GPCRs that have been resistant to traditional methods of drug screening.

Heptares Therapeutics focuses on the discovery and development of novel drugs acting at G-protein coupled receptors (GPCRs). Heptares StaR (Stabilized Receptor) technology enables thermo-stabilization of GPCRs, a breakthrough allowing X-ray crystallo...Show all

Company (Alive / Active)

Phone: +44 (0)1707 358 628

Fax:

BioPark, Broadwater Road
Welwyn Garden City
Hertfordshire, AL7 3AX
United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Heptares Therapeutics $61.2M May 18, 2017
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Heptares Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Novartis Venture FundsCorporate VentureBasel, SwitzerlandSeries A
ClarusVenture CapitalCambridge, Massachusetts, United StatesSeries B, Series A
MVM Life Science PartnersVenture CapitalLondon, England, United KingdomSeries A, Seed VC - II, Seed VC
Takeda VenturesCorporate VenturePalo Alto, California, United StatesSeries B, Series A - II
Stanley Medical Research InstitutionNon-Profit FoundationChevy Chase, Maryland, United StatesSeries B
See all 6 investors

Competitors

Company Status Description Investors
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Bicyclic aza compounds as muscarinic m1 receptor antagonists May 15, 2017 May 22, 2018 Patent
Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists May 10, 2017 Mar 27, 2018 Patent
Cgrp receptor antagonists May 05, 2017 Mar 27, 2018 Patent
Muscarinic m1 receptor agonists Feb 17, 2017 Mar 06, 2018 Patent
Orexin receptor antagonists Jan 18, 2017 Dec 26, 2017 Patent
See all 37 patents